New driver mutations in non-small-cell lung cancer (Q34161395)

31 July 2017

1 reference

title

New driver mutations in non-small-cell lung cancer (English)

1 reference

31 July 2017

1 reference

1

William Pao

1 reference

31 July 2017

Nicolas Girard

2

1 reference

31 July 2017

1 February 2011

1 reference

Lancet Oncology Commission

31 July 2017

1 reference

31 July 2017

12

1 reference

31 July 2017

2

1 reference

31 July 2017

175-180

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Characterizing the cancer genome in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

A mouse model for EML4-ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

The role of HER2/neu expression and trastuzumab in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Raf kinases: function, regulation and role in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

MEK1 mutations confer resistance to MEK and B-RAF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

PIK3CA mutation status in Japanese lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

PIK3CA mutation and amplification in human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Functional analysis of PIK3CA gene mutations in human colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

PIK3CA gene amplification in Japanese non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

AKT plays a central role in tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Uncommon V599E BRAF mutations in Japanese patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Activation of the MAP kinase pathway by the protein kinase raf

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Organization of the human hepatocyte growth factor-encoding gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Somatic mutations lead to an oncogenic deletion of met in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Integration of Molecular Profiling into the Lung Cancer Clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Somatic mutations of the protein kinase gene family in human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Epigenetics and cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970087-5

7 January 2021

10.1016/S1470-2045(10)70087-5

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

21277552